FDA Expands Biktarvy® Indication for HIV Treatment

- Biktarvy Now First and Only INSTI-Based Single-Tablet Regimen That is FDA Approved and DHHS Guideline Recommended for People Who are Virologically ...

February 27, 2024 | Tuesday | News
Bitterroot Bio and Biotheus Launch Joint Effort to Create Bispecific Proteins for Cardio-Immunology

Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, an...

February 27, 2024 | Tuesday | News
Boehringer Ingelheim plans to expedite the development of survodutide for MASH treatment

In a significant breakthrough for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), Boehringer Ingelheim's latest Phase II clinical...

February 26, 2024 | Monday | News
Sanofi's Rilzabrutinib Shows Promise in Phase 2 Trials for Chronic Spontaneous Urticaria

Sanofi-Aventis Groupe announced promising results from its Phase 2 RILECSU study, showcasing rilzabrutinib's ability to significantly reduce itch severity ...

February 26, 2024 | Monday | News
Tevogen Bio Launches Genetic Predisposition Study for Long COVID Treatment Advancements

Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) announces its strategic initiative to advance research into Long COVID treatment, unveiling plans ...

February 21, 2024 | Wednesday | News
Dyadic International, Inc. Teams Up with Israel Institute for Biological Research to Combat Emerging Diseases and Bio-Threats

Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a prominent global biotechnology company specializing in advanced microbial platform...

February 21, 2024 | Wednesday | News
Biocytogen Pharmaceuticals Announces Antibody Evaluation and Option Agreement with Gilead Sciences

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315)  announces an antibody evaluation and option agreement with Gil...

February 20, 2024 | Tuesday | News
Roche Diagnostics and BioPorto Announce Expanded Collaboration

    ProNephro AKI (NGAL) stands out as the first AKI biomarker test to secure FDA clearance for pediatric use, covering children from...

February 20, 2024 | Tuesday | News
Sarepta's ELEVIDYS Supplement Accepted by FDA for Duchenne Treatment Expansion

ChatGPT CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 16, 2024 07:00 AM Eastern Standard Time Sarepta Therapeutics, Inc. (NASDAQ:...

February 19, 2024 | Monday | News
Bayer AG and AskBio Initiate Phase II Trial of AB-1002 Gene Therapy for Congestive Heart Failure

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announ...

February 19, 2024 | Monday | News
Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)

  Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved...

February 16, 2024 | Friday | News
iNtRON Biotechnology Advances Cancer Treatment with PHAGERIA®, Harnessing Robot Bacteriophage Platform

  iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has unveiled a groundbreaking development in cancer treatment with the announcement of PHAGERI...

February 15, 2024 | Thursday | News
FDA Grants Orphan-Drug Designation to Mesoblast's Revascor® for Congenital Heart Disease in Children

Mesoblast's Chief Executive, Silviu Itescu, expressed satisfaction with the FDA's decision: “We are very pleased to have now been granted both Orphan...

February 15, 2024 | Thursday | News
Auron Therapeutics Unveils Groundbreaking Cancer Treatment Candidate AUTX-703 from AURIGIN™ Platform

    Auron Therapeutics, a pioneering biotechnology firm dedicated to advancing targeted cancer therapies, has announced the selection of its in...

February 08, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in